Acadia Pharmaceuticals Inc.

ACADIA PHARMACEUTICALS INC.

NASDAQ--ACAD

Acadia Pharmaceuticals Inc. is a bio-pharmaceutical company focused on
the discovery, development and commercialization of small molecule
drugs for the treatment of central nervous system disorders. In 2004,
Acadia had four drug programs in clinical development and several
additional programs in preclinical and discovery stages. The company's
three Phase II clinical programs are ACP-103 for treatment-induced
dysfunctions in Parkinson's disease, ACP-103 as an adjunctive therapy
for schizophrenia, and ACP-104 for the treatment of schizophrenia.
Acadia has retained worldwide commercialization rights for these
programs. The company also has a neuropathic pain program in Phase I
clinical trials and a glaucoma program in preclinical development,
each in collaboration with Allergan, Inc. Using its drug discovery
platform, Acadia has discovered all of the drug candidates in its
product pipeline.

Value

Total number of shares outstanding as of Feb. 3              23,500,000
Price of each share of common stock on Feb. 3                    $14.33
Aggregate market value as of Feb. 3.                       $336,755,000

Performance Record

For year ended Dec. 31, in thousands, except per-share data.

                                          2004         2003        2002

Total revenues                          $4,604       $7,378      $6,276
Net income (loss)                      $25,917      $14,092     $12,868
Net income (loss) per share               $.87        $1.46       $2.23
Total assets                           $40,365      $31,693     $16,023

Directors

Leslie Iversen, 67, chairman since 2000.

Gordon Binder, 69, director since 2003.

Mark Brann, 46, director since 1997.

Mary Ann Gray, 52, director since 2005.

Uli Hacksell, 54, director since 2000.

Lester Kaplan, 54, director since 1997.

Torsten Rasmussen, 60, director since 1998.

Martien van Osch, 34, director since 2003.

Alan Walton, 69, director since 2003.

Executive Compensation

Officer                                          2004 Cash Compensation

Uli Hacksell, chief executive officer                          $435,933
Mark Brann, president and chief scientific
  officer                                                      $365,681
Bo-Ragnar Tolf, vice president, chemistry and
  managing director                                            $321,927
Thomas Aasen, vice president and chief
  financial officer                                            $309,687
Robert Davis, executive vice president,
drug discovery development                                     $308,564

Significant Stock Ownership

                                                 * Number     * Percent
                                                 of shares
                                                  Jan. 31

Alan Walton                                      2,608,815         14.4
Oxford Bioscience Partners IV affiliates         2,599,815         14.4
Lonmodtagernes Dyrtidsfond                       1,123,952          6.2
SepracorInc.                                     1,077,029            6
OrbiMed Advisors LLC affiliates                  1,036,009          5.7
Wellington Management Co. LLP affiliates         1,000,514          5.5
Federated Kaufmann Fund affiliates                 936,009          5.2
Directors and officers as a group (13 people)    6,748,956         30.1

* The beneficially owned number of shares and percentages were drafted
exactly from the proxy statement, which includes duplications.

Other Information

Headquarters: 3911 Sorrento Valley Blvd., San Diego, CA 92121;
[phone]; fax [phone].

Web site: www.acadiapharln.com.

Auditors: PricewaterhouseCoopers LLP.

Employees: 101.

Industry: Biotech.

Information was compiled from the company's annual and proxy reports.